MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q1
hinzugefügt 15.05.2023
9 Meters Biopharma Betriebsaufwand 2011-2026 | NMTR
Betriebsaufwand Jährlich 9 Meters Biopharma
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 42 M | 36.8 M | 60.9 M | 24.3 M | 18.2 M | 6.6 M | 6.68 M | 6.89 M | 6.91 M | 3.97 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 60.9 M | 3.97 M | 21.3 M |
Betriebsaufwand Vierteljährlich 9 Meters Biopharma
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.8 M | - | 8.72 M | 11.2 M | 11.4 M | - | 13.5 M | 8.26 M | 5.4 M | - | 6.3 M | 44.8 M | 4.96 M | - | 6.51 M | 6.12 M | 4.31 M | - | -220 K | 3.38 M | 11.3 M | - | 2.34 M | 2.69 M | 3.92 M | - | 2.46 M | 1.33 M | 1.68 M | - | 1.92 M | 1.14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 44.8 M | -220 K | 7.34 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
ADMA Biologics
ADMA
|
101 M | $ 16.45 | 0.43 % | $ 3.92 B |  USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
ANI Pharmaceuticals
ANIP
|
127 M | $ 76.96 | 1.13 % | $ 1.49 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.83 | 4.23 % | $ 4.53 M |  China |
 |
Graybug Vision
GRAY
|
23.1 M | - | -11.23 % | $ 9.65 M | USA |
 |
AbCellera Biologics
ABCL
|
292 M | $ 3.66 | -1.48 % | $ 1.09 B |  Canada |
 |
BridgeBio Pharma
BBIO
|
304 M | $ 66.52 | 3.08 % | $ 12.7 B | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | China |
 |
Apellis Pharmaceuticals
APLS
|
948 M | $ 19.91 | -1.24 % | $ 2.51 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
44.9 M | - | - | $ 521 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 60.66 | 3.64 % | $ 11.6 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 8.4 | -1.81 % | $ 1.39 B | Britain |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 164.17 | 0.07 % | $ 8.17 B | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Cabaletta Bio
CABA
|
74.7 M | $ 3.39 | 4.31 % | $ 3.96 M | USA |
 |
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
Capricor Therapeutics
CAPR
|
49.3 M | $ 26.0 | 0.62 % | $ 696 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 2.84 | 1.07 % | $ 908 M |  Israel |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
425 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | USA |
 |
Codexis
CDXS
|
31.5 M | $ 1.1 | 11.73 % | $ 80.7 M | USA |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.78 | 7.58 % | $ 168 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
47.8 M | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
12.4 M | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
12 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
12 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
226 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Certara
CERT
|
237 M | $ 7.3 | 0.76 % | $ 1.17 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
206 M | $ 24.67 | 3.14 % | $ 3.02 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |